Tag : Epidiolex

Current News Hemp News Market Watch

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®. The clinical results have shown that their product has significantly helped patients with Dravet syndrome treat and reduce their seizures associated with the...
Global Health Hemp News Market Watch

GW Pharma to Raise $300M Via Public Offering

Editor
GW Pharmaceuticals plc (NASDAQ: GWPH) announced this morning that the company’s wholly owned subsidiary, Greenwich Biosciences, plans to raise $300 million dollars via the selling GW Pharma’s common shares on the NASDAQ Global Market. The company is planning to offer the underwriters an additional 30-day option to purchase an additional $45...
Politics

DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug

Editor
The Drug Enforcement Administration (DEA) has given the Cannabidiol (CBD) derived pharmaceutical product, Epidiolex, a reported Schedule V status. The newly approved drug is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The CBD product Epidiolex is derived from the cannabis...
Health Hemp News Market Watch

FDA Approves GW Pharma’s CBD Derived Epidiolex to Treat Epilepsy

Editor
The United States Food & Drugs Administration (FDA) has officially approved GW Pharmaceuticals’ (NASDAQ: GWPH) Cannabidiol (CBD) derived medication called Epidiolex. The newly approved drug is a oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The new CBD derived pharmaceutical will be...
Hemp News Market Watch

GW Pharmaceuticals CBD Based Drug Could Receive FDA Approval Soon

Editor
WASHINGTON (AP) — A medicine made from the marijuana plant moved one step closer to U.S. approval Thursday after federal health advisers endorsed it for the treatment of severe seizures in children with epilepsy. If the Food and Drug Administration follows the group’s recommendation, GW Pharmaceuticals’ syrup would become the...
Hemp News Market Watch

GW Pharmaceuticals Receives Approval for 5 New Patents for Epidiolex

Editor
GW Pharmaceuticals (Nasdaq:GWPH) recently announced that their company has received “Notices of Allowance” from the United States Patent and Trademark office for five new Epidiolex® patent applications for the company’s proprietary Cannabidiol (CBD) based pharmaceutical. Epidiolex® is concentrated on treating rare, treatement resistant epilepsy conditions such as Dravet syndrome, Lennox-Gastaut...
Current News Health Market Watch

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

Editor
On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s...